Alpha 2.0
Login Register
» Authors » Aakash Mahant Mahant

Aakash Mahant Mahant

Explore the profile of Aakash Mahant Mahant including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 33
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pediatrics
Top 10 Co-Authors
Betsy C Herold
Clare Burn Aschner
Sandra Guerguis
Kathryn Anastos
Matthew S Gromisch
Jacqueline M Achkar
Simone Sidoli
Steven C Almo
Sharlene Sy
Tamara P Blevins
Published In
Vaccines (Basel)
Viruses
J Pediatric Infect Dis Soc
J Infect Dis
J Clin Invest
Affiliations
Soon will be listed here.
Recent Articles
1.
Novel Mouse Model of Recurrent Sublethal Herpes Simplex Virus Infection Recapitulates Human Antibody Responses to Primary and Chronic Infection
Mahant A, Gualdron T, Herold B
Vaccines (Basel) . 2024 Oct; 12(10). PMID: 39460294
Herpes simplex virus (HSV) vaccine development has been impeded by the absence of predictive preclinical models and defined correlates of immune protection. Prior candidates elicited neutralizing responses greater than natural...
2.
Antibody attributes, Fc receptor expression, gestation and maternal SARS-CoV-2 infection modulate HSV IgG placental transfer
Mahant A, Trejo F, Aguilan J, Sidoli S, Permar S, Herold B
iScience . 2023 Sep; 26(9):107648. PMID: 37670782
Antibody-dependent cellular cytotoxicity (ADCC) is associated with protection against neonatal herpes. We hypothesized that placental transfer of ADCC-mediating herpes simplex virus (HSV) immunoglobulin G (IgG) is influenced by antigenic target,...
3.
Greater Durability and Protection against Herpes Simplex Viral Disease following Immunization of Mice with Single-Cycle ΔgD-2 Compared to an Adjuvanted Glycoprotein D Protein Vaccine
Mahant A, Gromisch M, Kravets L, Aschner C, Herold B
Vaccines (Basel) . 2023 Aug; 11(8). PMID: 37631930
Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D (gD), failed to provide durable protection. We adopted a...
4.
Prolonged Preterm Rupture of Membranes Associated with Neonatal Disseminated Herpes Simplex Virus Type 1 at Birth: Is There a Role for Preemptive Test and Treat Strategies in High-Risk Populations?
Estrada F, Mahant A, Guerguis S, Sy S, Lu C, Reznik S, et al.
J Pediatric Infect Dis Soc . 2023 Mar; 12(4):246-247. PMID: 37001048
No abstract available.
5.
A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice
Kuraoka M, Aschner C, Windsor I, Mahant A, Garforth S, Kong S, et al.
J Clin Invest . 2022 Dec; 133(3. PMID: 36454639
There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies,...
6.
Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines
Mahant A, Guerguis S, Blevins T, Cheshenko N, Gao W, Anastos K, et al.
J Infect Dis . 2022 Jul; 226(9):1489-1498. PMID: 35834278
Background: The glycoprotein D (gD)/AS04 vaccine failed to prevent herpes simplex virus (HSV) 2 in clinical trials. Failure was recapitulated in mice, in which the vaccine elicited neutralizing antibody but...
7.
Antibodies Elicited in Response to a Single Cycle Glycoprotein D Deletion Viral Vaccine Candidate Bind C1q and Activate Complement Mediated Neutralization and Cytolysis
Visciano M, Mahant A, Pierce C, Hunte R, Herold B
Viruses . 2021 Jul; 13(7). PMID: 34209320
Herpes simplex virus (HSV) prevention is a global health priority but, despite decades of research, there is no effective vaccine. Prior efforts focused on generating glycoprotein D (gD) neutralizing antibodies,...